Opinion
Video
Third-Line Treatment Options in mCRC: A Clinical Overview
Experts provide an overview of third-line treatment options for metastatic colorectal cancer (mCRC) in patients with disease progression through all available regimens, focusing on fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab.
Video content above is prompted by the following:
- Provide an overview of the third-line treatment options for mCRC for patients with disease that has progressed through all available regimens.
- Fruquintinib
- Regorafenib
- Trifluridine + tipiracil ± bevacizumab
Related Videos
Related Content
